ATE511395T1 - Mittel zur behandlung von glomerulopathie - Google Patents

Mittel zur behandlung von glomerulopathie

Info

Publication number
ATE511395T1
ATE511395T1 AT02720493T AT02720493T ATE511395T1 AT E511395 T1 ATE511395 T1 AT E511395T1 AT 02720493 T AT02720493 T AT 02720493T AT 02720493 T AT02720493 T AT 02720493T AT E511395 T1 ATE511395 T1 AT E511395T1
Authority
AT
Austria
Prior art keywords
glomerular
glomerulopathy
agents
treatment
preventive
Prior art date
Application number
AT02720493T
Other languages
English (en)
Inventor
Takashi Nakagawa
Makoto Suda
Yoichi Yamauchi
Original Assignee
Kowa Co
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co, Nissan Chemical Ind Ltd filed Critical Kowa Co
Application granted granted Critical
Publication of ATE511395T1 publication Critical patent/ATE511395T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02720493T 2001-04-19 2002-04-18 Mittel zur behandlung von glomerulopathie ATE511395T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001121058 2001-04-19
JP2001361257 2001-11-27
PCT/JP2002/003870 WO2002085363A1 (en) 2001-04-19 2002-04-18 Remedial agent for glomerular disease

Publications (1)

Publication Number Publication Date
ATE511395T1 true ATE511395T1 (de) 2011-06-15

Family

ID=26613829

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02720493T ATE511395T1 (de) 2001-04-19 2002-04-18 Mittel zur behandlung von glomerulopathie

Country Status (6)

Country Link
US (1) US7504415B2 (de)
EP (1) EP1386608B1 (de)
JP (1) JP4235000B2 (de)
AT (1) ATE511395T1 (de)
PT (1) PT1386608E (de)
WO (1) WO2002085363A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085363A1 (en) 2001-04-19 2002-10-31 Kowa Co., Ltd. Remedial agent for glomerular disease
MY131170A (en) * 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
JPWO2006046528A1 (ja) * 2004-10-29 2008-05-22 興和株式会社 糸球体疾患治療剤
WO2008082537A2 (en) 2006-12-19 2008-07-10 The General Hospital Corporation Compounds for modulating integrin cd11b/cd18
AU2013248972A1 (en) 2012-04-20 2014-11-13 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JPH08198898A (ja) 1995-01-30 1996-08-06 Takeda Chem Ind Ltd コレステロール搬出促進物質
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US6147109A (en) 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
IL152079A0 (en) * 2000-04-12 2003-05-29 Novartis Ag Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
CA2420844A1 (en) 2000-08-30 2003-02-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
HUP0303353A3 (en) 2000-10-12 2004-10-28 Kowa Co Preventives and remedies for complications of diabetes
WO2002085363A1 (en) 2001-04-19 2002-10-31 Kowa Co., Ltd. Remedial agent for glomerular disease

Also Published As

Publication number Publication date
PT1386608E (pt) 2011-07-26
WO2002085363A1 (en) 2002-10-31
EP1386608A1 (de) 2004-02-04
EP1386608B1 (de) 2011-06-01
US20040116468A1 (en) 2004-06-17
EP1386608A4 (de) 2005-02-09
US7504415B2 (en) 2009-03-17
JP4235000B2 (ja) 2009-03-04
JPWO2002085363A1 (ja) 2004-08-05

Similar Documents

Publication Publication Date Title
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
CY1111951T1 (el) Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου
EP1780197A4 (de) 5-substituiertes 2-phenylaminobenzamid als mek-inhibitor
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
ATE272398T1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
EA200401114A2 (ru) Замещённые гидроксиэтиламины
DE502004006619D1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE103808T1 (de) N-(3,4-dimethoxycinnamoyl)-anthranilsaeure enthaltende arzneimittelzusammensetzungen.
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
ATE550039T1 (de) Mittel zur behandlung von glomerulären erkrankungen
DE60002558D1 (de) Derivate der Phosphonsäure zur Inhibierung von Carboxypeptidase B
IL150965A0 (en) Therapeutic or preventive agent for digestive system diseases containing a diaminotrifluoromethylpyridine derivative
ATE511395T1 (de) Mittel zur behandlung von glomerulopathie
EP1256581A4 (de) Vorbeugende oder therapeutische mittel für gastriche oder ösophageale regurgitation
KR970706811A (ko) I형 알레르기성 질환의 예방 및 치료제(Preventive and remedy for type Ⅰ allergic diseases)
ATE332697T1 (de) Cyanidinmischung zur behandlung von dickdarmkrebs
DK1174131T3 (da) Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
ATE305783T1 (de) Verwendung von diaminotrifluoromethylpyridinderivaten für die prevention und behandlung von lebererkrankungen
BR0214780A (pt) Sal de ácido cìtrico de um composto terapêutico e composições farmacêuticas deste
EP1325918A4 (de) Herzmuskelzellen-apoptose hemmstoffe und behandlung/vorbeugung von herzkrankheiten
DE60143671D1 (de) Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor-antagonists
ATE359778T1 (de) Mittel zur behandlung von myelopathie
TH51180A (th) วิธีสำหรับการรักษาโรคพาร์คินสันโดยการให้ (-)-5- คีโท-2-N,N-ได-n-โปรพิลอะมิโน-เตตระไฮโดรเตตระลิน

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties